BOCIC(SH:601696) Xin Lang Cai Jing·2025-09-09 02:16Group 1 - The core viewpoint of the news is that Junshi Biosciences has seen a stock price increase of 5.11%, reaching 49.96 CNY per share, with a trading volume of 315 million CNY and a turnover rate of 0.84%, resulting in a total market capitalization of 51.293 billion CNY [1] - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its main business revenue coming from drug sales [1] - The company is headquartered in Shanghai, with additional offices in Hong Kong, and was listed on July 15, 2020 [1] Group 2 - According to data, a fund under Bank of China Securities holds a significant position in Junshi Biosciences, with 223,000 shares, accounting for 4.8% of the fund's net value, making it the sixth-largest holding [2] - The Bank of China Securities Health Industry Mixed Fund (002938) has achieved a year-to-date return of 64.93% and a one-year return of 71.98%, ranking 268 out of 8179 and 1158 out of 7984 in its category, respectively [2] - The fund manager, Li Mingwei, has been in position for 2 years and 201 days, with the fund's total asset size at 158 million CNY [3]